Lunai Bioworks (LNAI) Receivables (2012 - 2025)

Lunai Bioworks (LNAI) posted quarterly Receivables of $1.1 million for Q1 2025, up 1.66% quarter-over-quarter from $1.1 million in Q4 2023.

Lunai Bioworks (LNAI) Receivables (2012 - 2025) Analysis & Trends

Lunai Bioworks' Receivables history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2025.

In Q1 2025, Receivables changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2025 stood at $1.1 million (changed N/A YoY), while the FY2016 annual figure was $1.4 million, up 221.86% from the prior year.
Receivables for Q1 2025 stood at $1.1 million, up from $1.1 million in the prior quarter.
The five-year high for Receivables was $1.1 million in Q1 2025, with the low at $1.1 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.56 Bn	78.56 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.72 Bn	60.53 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.75 Bn	53.61 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.59 Bn	10.19 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.63 Bn	26.47 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.24 Bn	26.40 Bn	-	-
10	Lunai Bioworks	7.03 Mn	3.87 Mn	20,942.00	-

Download Data